| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3759 | 2016 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3336 | 2013 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1968 | 2020 |
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ... Journal of clinical oncology 28 (20), 3219-3226, 2010 | 1893 | 2010 |
| Chemotherapy for advanced gastric cancer AD Wagner, NLX Syn, M Moehler, W Grothe, WP Yong, BC Tai, J Ho, ... Cochrane database of systematic reviews, 2017 | 1865 | 2017 |
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data AD Wagner, W Grothe, J Haerting, G Kleber, A Grothey, WE Fleig Journal of clinical oncology 24 (18), 2903-2909, 2006 | 1643 | 2006 |
| Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ... Journal of clinical oncology 27 (22), 3677-3683, 2009 | 1564 | 2009 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1458 | 2019 |
| Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment A Grothey, D Sargent, RM Goldberg, HJ Schmoll Journal of Clinical Oncology 22 (7), 1209-1214, 2004 | 1374 | 2004 |
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with … J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ... The Lancet Oncology 16 (5), 499-508, 2015 | 1076 | 2015 |
| Duration of adjuvant chemotherapy for stage III colon cancer A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ... New England Journal of Medicine 378 (13), 1177-1188, 2018 | 1054 | 2018 |
| NCCN guidelines insights: colon cancer, version 2.2018 AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018 | 974 | 2018 |
| Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ... Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018 | 936 | 2018 |
| Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) A Grothey, MM Sugrue, DM Purdie, W Dong, D Sargent, E Hedrick, ... Journal of clinical oncology 26 (33), 5326-5334, 2008 | 928 | 2008 |
| Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates G Folprecht, A Grothey, S Alberts, HR Raab, CH Köhne Annals of Oncology 16 (8), 1311-1319, 2005 | 857 | 2005 |
| Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies S Wolf, D Barton, L Kottschade, A Grothey, C Loprinzi European journal of cancer 44 (11), 1507-1515, 2008 | 831 | 2008 |
| A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group HO Al‐Shamsi, W Alhazzani, A Alhuraiji, EA Coomes, RF Chemaly, ... The oncologist 25 (6), e936-e945, 2020 | 826 | 2020 |
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 804 | 2005 |
| Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, L Cederquist, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 15 (3), 370-398, 2017 | 796 | 2017 |
| Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ... JAMA oncology 5 (7), 1008-1019, 2019 | 780 | 2019 |
Daniel SargentMayo ClinicVerified email at mayo.edu
